Skip to main content
. Author manuscript; available in PMC: 2014 Jan 7.
Published in final edited form as: Handb Exp Pharmacol. 2011;(200):10.1007/978-3-642-13443-2_6. doi: 10.1007/978-3-642-13443-2_6

Table 7.

Adenosine receptor affinities of functionalized xanthines as molecular probes

Ki (nM)a
A1 A2A A2B A3
Spin-labeled probes
155 5.47 (r)1 8,780 (r)1 >1,000 (h)1 1,700 (h)1
156 8.23 (r)1 3,800 (r)1 3,100 (h)1 ca. 10,000 (h)1
157 15.7 (r)1 1,270 (r)1 48 (h)1 350 (h)1
167 TEMPO-XAC 4.9 (r)2
0.30 (c)2
nd nd nd
Irreversible ligands
158 FSCPX3,4 10 (r)3 nd nd nd
160 ISC 42,600 (r)5
51,400 (gp)5
89,500 (rb)5
63,400 (c)5
146 (r)5
160 (gp)5
413 (rb)5
516 (c)5
nd nd
164 m-DITC-XAC 2.39 (r)6
52 (r)7
nd nd nd
165 p-DITC-XAC 6.60 (r)6
27 (r)7
nd nd nd
Radioligands
159 [18F]CPFPX 1.26 (h)8
0.63 (r)8
1.37(p)8
0.18 (c)8
940 (h)8
812 (r)8
nd nd
166 40 [IC50] (c) 9 nd nd nd
172 [125I]PAPA-XAC 0.1 (c)10 nd nd nd
Biotin conjugates
161 54 (r)11,12 nd nd nd
162 50 (r)11,12 nd nd nd
163 60 (r)12 nd nd nd
Various conjugates
168 D-Lys-XAC 1.74 [IC50] (r) 13 159 [IC50] (r)13 nd nd
169 35 (r)12 nd nd nd
170 8.1 (r)2
0.8 (c)2
nd nd nd
171 DTPA-XAC 59.5 (r)2
3.25 (c)2
nd nd nd
Fluorescent ligands
173 FITC-XAC 125 (r)2
9.3 (c)2
nd nd nd
174 XAC-BY630 151 (h)14 nd nd nd
Bivalent ligand conjugates
17511,15 31 (r) nd nd nd
176 A2A antagonist/D2 agonist for A2A/D2 receptor heteromers
Ki D2 (s) = 1.0 nM)16
nd 55 (s)16 nd nd